Laura Olson, APRN
Family · Las Vegas, NVNPI 1255703799
Payments from drug & device makers
Across 268 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$640
- Lilly USA, LLC$466
- Sanofi-aventis U.S. LLC$456
- Amgen$385
- Esperion Therapeutics, Inc.$295
- Insulet Corporation$281
- plus $4K from 36 others
What the payments were for
- Food & beverage$6,025100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$367
- MINIMED 780G$168
- TWIIST$150
- Omnipod$137
- NEXLIZET$125
- NEXLETOL$125
- Veozah$124
- Ozempic$121
- MOUNJARO$120
- TZIELD$116
- DEXCOM G6 TRANSMITTER$103
How this compares
$6,036 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 194 | $227,368 |
| JardianceEmpagliflozin | 117 | $144,217 |
| MounjaroTirzepatide | 76 | $88,532 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 96 | $86,610 |
| TrulicityDulaglutide | 56 | $84,166 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $49,429 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $39,670 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $34,890 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $27,406 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 153 | $21,237 |
| Humalog Kwikpen U-100Insulin Lispro | 78 | $20,915 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $19,907 |
| RybelsusSemaglutide | 21 | $19,687 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $19,660 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 104 | $11,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $640 | $247,055215 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $107 | $187,594170 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $466 | $185,706180 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $456 | $86,61096 claims |
| AbbVieSynthroid | $88 | $2,43721 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $253 | $1,930164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Kelly PapeshLas Vegas$44K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.